China Universal NASDAQ Biotechnology Technology ETF(QDII)(513290.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
China Universal NASDAQ Biotechnology Technology ETF(QDII)
513290.SH
News
View More

Amgen Inc. Rallies After Repatha Trial Win And Strong Quarterly Results

Amgen Inc. (Nasdaq: AMGN) experienced a surge following a successful late-stage trial for Repatha and a significant earnings beat, reporting $9.557B in revenue against an estimate of $9.146B. The stock has risen from $259.28 to $323.66, nearing its 52-week high. Analysts maintain a strong sentiment with a score of 85.71, indicating a mix of Buy and Strong Buy ratings. The positive momentum is supported by strong cardiovascular data for Repatha, which could enhance market share and revenue growth. The Trade Engine Score stands at 60.38, suggesting favorable market conditions.

Talkmarkets·
US
AMGN
+3.81%
Talkmarkets·
US
AMGN
+3.81%

AstraZeneca to invest $2 billion as part of US manufacturing push

AstraZeneca plans to invest $2 billion to expand its manufacturing in Maryland, supporting 2,600 jobs. This is part of a $50 billion U.S. expansion plan by 2030, aligning with Trump's domestic manufacturing push. The investment will enhance biologics production and create new facilities, boosting drug supply and creating skilled jobs. The expansion includes facilities in Frederick and Gaithersburg, contributing to AstraZeneca's broader U.S. growth strategy.

Reuters·
US
AZN
+0.67%
UK
AZN
0.00%
Reuters·
US
AZN
+0.67%
UK
AZN
0.00%

AstraZeneca to acquire Modella AI to speed oncology drug research

AstraZeneca has agreed to acquire Modella AI to enhance its oncology drug research using artificial intelligence. The financial terms were not disclosed. Modella AI's technology will support clinical development and biomarker discovery, addressing the complexities of oncology drug development. This acquisition marks the first by a major pharmaceutical company in the AI sector. AstraZeneca aims to integrate AI capabilities to improve patient selection for drug trials, potentially increasing clinical success rates and reducing costs. The deal follows a previous collaboration between the two companies.

Reuters·
UK
AZN
0.00%
US
AZN
+0.67%
Reuters·
UK
AZN
0.00%
US
AZN
+0.67%

17:31 ET Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight

The castration-sensitive prostate cancer (CSPC) market is projected to grow at a 13.2% CAGR from 2020 to 2034, driven by aging demographics, improved screening, and new therapies. The market size is expected to reach USD 4.3 billion in 2024, with the U.S. holding 66% of this market. Key players include AstraZeneca, Johnson & Johnson, and Pfizer, with emerging therapies like TRUQAP and TALZENNA showing promise. The rise in prostate cancer cases, particularly among older populations, and advancements in mutation-targeted therapies are expected to further boost market growth.

prnewswire·
US
JNJ
-0.09%
US
AZN
+0.67%
prnewswire·
US
JNJ
-0.09%
US
AZN
+0.67%

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Regeneron's Lynozyfic, an antibody drug approved by the FDA, eradicates residual multiple myeloma cells in a small trial, potentially avoiding bone marrow transplants. None of the 18 participants showed detectable residual disease after treatment. The trial aims to enroll 50 patients, with expectations of prolonged cancer-free survival. Additionally, a study suggests GLP-1 weight-loss drugs likely do not affect cancer risks, and smartphone ownership in pre-teens is linked to health risks.

Reuters·
US
REGN
+2.12%
Reuters·
US
REGN
+2.12%
© 2026 Longbridge｜Disclaimer